and a pulmonary arterial systolic pressure of 65 mm Hg (normal, <35). How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome.

The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Tablets for heart failure patients.

but I-PRESERVE excluded patients who had a prior documented ejection fraction <40%, which minimized the confounder that patients with systolic heart failure whose ejection fraction might have ...

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Diastolic heart failure is defined clinically when signs and symptoms of heart failure are present in the presence of preserved left ventricular systolic function (ejection fraction >45%).

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Lupin receives US FDA approval for sacubitril and valsartan tablets: Our Bureau, Mumbai Friday, January 24, 2025, 15:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) announc ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.